Sign in
Enrolling by invitationPhase 3

Long-term safety of tenapanor in children and teens with irritable bowel syndrome with constipation

Tests tenapanor's long-term safety in children and teens with irritable bowel syndrome with constipation.

Key facts

Who runs it
Ardelyx
Where
Abilene, Anaheim, Boys Town, Brooklyn, Charlotte, Doral, Durham, El Paso, Foley, Greenville, Harlingen, Indianapolis, Kingwood, Kissimmee, Mankato, Miami, Orlando, Peoria, Plano, Portland, San Antonio, Scottdale, Smithfield, South Miami, Sugar Land, The Bronx, and Wilmington, United StatesSee the 27 sites
Trial code
Registry title
Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C
Status
Enrolling by invitation
Phase
Phase 3
People taking part
150 people, planned
Started
17 Feb 2023
Expected to end
Oct 2031
Type of study
Interventional
Treatments tested
  • Tenapanor
Record updated
4 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and teens with irritable bowel syndrome with constipation (IBS-C) who just finished an earlier tenapanor study. They will keep taking tenapanor so its long-term safety can be studied.

Age
≥6 and <18 years old at enrollment of the earlier (parent) study.
Sex
All sexes can join.
Disease stage
Irritable bowel syndrome with constipation (IBS-C). The person must be able to walk.
Earlier treatment
Must have finished the earlier (parent) study right before this one, following its procedures well.
Biomarker or test result
Girls who can become pregnant need a negative pregnancy test at the last visit of the earlier study. They must use birth control, which can include not having sex.

Main reasons for not taking part

  • Stopped the earlier study early
  • Any surgery on the stomach, small intestine or colon, except removal of the appendix or gallbladder
  • Pregnant or breastfeeding
  • Unable or unwilling to follow the study rules, in the opinion of the study doctor

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • ≥6 and <18 years old at enrollment of either parent study
  • Patient completed the parent study immediately with adequate compliance with study procedures in the opinion of the Investigator
  • Females of child-bearing potential must have negative pregnancy test at the last visit of the parent study and confirm the use of appropriate contraception (including abstinence)
  • Subject is ambulatory
  • Written informed consent by parent/guardian/ Legally Authorized Representative (LAR) and a willingness of both subject and parent/guardian/LAR to participate in the study as it is described

Who cannot take part

  • Any surgery on the stomach, small intestine or colon, excluding appendectomy or cholecystectomy
  • Patient discontinued prematurely from the parent study
  • Pregnant or lactating women
  • If, in the opinion of the Investigator, patient is unable or unwilling to fulfill the requirements of the protocol

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 6 and 18 years old?

Where in United States

  • Advance Clinical Trial PLLCAbilene, United StatesEnrolling by invitation
  • Advanced Research Center, Inc.Anaheim, United StatesEnrolling by invitation
  • Boys Town National Research HospitalBoys Town, United StatesEnrolling by invitation
  • SUNY Downstate Medical CenterBrooklyn, United StatesEnrolling by invitation
  • Atrium HealthCharlotte, United StatesEnrolling by invitation
  • Prohealth Research CenterDoral, United StatesEnrolling by invitation
  • Duke University School of MedicineDurham, United StatesEnrolling by invitation
  • Maspons Pediatric GastroEl Paso, United StatesEnrolling by invitation
  • G & L Research LLCFoley, United StatesEnrolling by invitation
  • Prisma Health Children's HospitalGreenville, United StatesEnrolling by invitation
  • Texas Digestive SpecialistsHarlingen, United StatesEnrolling by invitation
  • Riley Children's HealthIndianapolis, United StatesEnrolling by invitation
  • Frontier Clinical ResearchKingwood, United StatesEnrolling by invitation
  • I.H.S Health, LLCKissimmee, United StatesEnrolling by invitation
  • Mankato Clinic/ Javara Research LtdMankato, United StatesEnrolling by invitation
  • Valencia Medical and Research CenterMiami, United StatesEnrolling by invitation
  • Orlando Health, Inc.- APH Center for Digestive Health and NutritionOrlando, United StatesEnrolling by invitation
  • OSF Saint Francis Medical CenterPeoria, United StatesEnrolling by invitation
  • Aim Trials, LLCPlano, United StatesEnrolling by invitation
  • Maine HealthPortland, United StatesEnrolling by invitation
  • Sun Research InstituteSan Antonio, United StatesEnrolling by invitation
  • Frontier Clinical Research, LLCScottdale, United StatesEnrolling by invitation
  • Frontier Clinical Research, LLCSmithfield, United StatesEnrolling by invitation
  • Florida Pharmaceutical Research and Associates, Inc.South Miami, United StatesEnrolling by invitation
  • Pioneer Research Solutions IncSugar Land, United StatesEnrolling by invitation
  • Advantage Clinical TrialsThe Bronx, United StatesEnrolling by invitation
  • Wilmington HealthWilmington, United StatesEnrolling by invitation

About the trial

What the trial wants to find out

Open-label long-term safety study of tenapanor in pediatric patients with IBS-C.

The group in the trial

  • TenapanorTreatment being tested

    Eligible patients from the parent study will continue tenapanor at the same dose assigned in the parent study which can be titrated to either 50 mg BID or 25 mg BID per Investigator guidance after a patient's first week on the assigned dose.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open-Label Long-Term Safety Study of Tenapanor for the Treatment of Irritable Bowel Syndrome With Constipation (IBS-C) in Pediatric Patients 6 to Less Than 18 Years Old
Plain-language title
Long-term safety of tenapanor in children and teens with irritable bowel syndrome with constipationGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT05905926, who can take part
Record updated
4 June 2026